CB21

CB21 refers to two distinct entities in the pharmaceutical and biotech space: 1. **Cartography Biosciences' CB21** is a highly-potent T-cell engager molecule in late preclinical development for the treatment of colorectal cancer. It specifically targets Lymphocyte antigen 6 complex locus G6D (LY6G6D), an emerging tumor-specific antigen identified as relevant for colorectal cancer therapy. The drug is designed to engage T-cells and direct them against tumor cells expressing Lymphocyte antigen 6 complex locus G6D (LY6G6D), with the goal of minimizing impact on healthy cells. Cartography Biosciences developed this candidate using their ATLAS platform, which analyzes patient tissue samples to identify optimal therapeutic targets[1][4]. 2. **CB21 Pharma** is a Czech pharmaceutical company specializing in cannabinoid-based active pharmaceutical ingredients (APIs) and medical devices derived from cannabis extracts, such as cannabidiol (CBD). Their products include GMP-certified APIs and CE-certified suppositories for vaginal and rectal use, marketed under trade names like CANNEFF VAG SUP and CANNEFF SUP. These are used primarily for symptom relief after gynecological or proctological procedures or conditions but are not directly referred to as "CB21" drugs; rather, "CB21" here refers to the company itself[5][7].